Death-related factors in HIV/AIDS patients undergoing  hemodialysis in an intensive care unit by Cavalcante, Malena Gadelha et al.
Rev Inst Med Trop São Paulo. 2021;63:e33 Page 1 of 6
ORIGINAL ARTICLE
http://doi.org/10.1590/S1678-9946202163033
This is an open-access article distributed under the 
terms of the Creative Commons Attribution License.
1Universidade Federal do Ceará, Faculdade 
de Medicina, Fortaleza, Ceará, Brazil
2Universidade de Fortaleza, Curso de 
Medicina, Fortaleza, Ceará, Brazil
Correspondence to: Malena Gadelha 
Cavalcante 
Universidade do Ceará, Faculdade de 
Medicina, Rua Ines Dantas de Menezes, 
333, Castelão, CEP 60867-570, Fortaleza, 
CE, Brazil 
Tel: +55 85 99757-5761
E-mail: malenagadelha@hotmail.com
Received: 27 November 2020
Accepted: 19 March 2021
Death-related factors in HIV/AIDS patients undergoing 
hemodialysis in an intensive care unit
Malena Gadelha Cavalcante 1, Matheus de Sá Roriz Parente 1, Pedro 
Eduardo Andrade de Carvalho Gomes 1, Gdayllon Cavalcante Meneses 1,  
Geraldo Bezerra da Silva Júnior 1,2, Roberto da Justa Pires Neto 1, 
Elizabeth De Francesco Daher 1
ABSTRACT
HIV-infected patients are at high risk for developing critical diseases, including 
opportunistic infections (OI), with consequent admission in intensive care units (ICU). 
Renal disfunctions are risk factors for death in HIV/AIDS patients, and survival rates 
in patients undergoing hemodialysis are smaller than the ones observed in the general 
population. In this context, this study aimed to investigate death-related factors in 
HIV/AIDS patients in an intensive care setting. This is a retrospective cross-sectional study 
performed through the analysis of medical records from 271 HIV/AIDS-diagnosed patients 
hospitalized in an intensive care unit of an infectious disease hospital, in Fortaleza, Ceara 
State, Brazil. Patients were divided into two groups: those who underwent dialysis during 
hospitalization and those who did not. Clinical and demographic parameters that could be 
associated with death were evaluated. Results indicated a prevalence of death of 19.1% 
(CI 95%: 14.8-24.3). The median age of patients was 47 years, with a male predominance 
(71.3%). The main causes of admission were pulmonary tuberculosis (16.9%), followed 
by neurotoxoplasmosis (14.9%). In the bivariate analysis, for those that did not undergo 
dialysis, age, fever, dyspnea, oliguria, disorientation, kidney injury, use of lamivudine and 
efavirenz, length of hospitalization, CD4 count, WBC count, platelet count, urea, sodium 
and LDH levels were the associated variables. In those who needed dialysis, the use of 
stavudine, abacavir and ritonavir, and the length of hospitalization were associated factors. 
Renal toxicity by the antiretroviral agents and length of hospitalization increased the risk 
of death among HIV patients under dialysis.
KEYWORDS: HIV. AIDS. Intensive Care Unit. Death. Dialysis. Renal failure. 
INTRODUCTION
According to the United Nations Program on HIV/AIDS (UNAIDS), there were 
38 million people with human immunodeficiency virus (HIV) and 690 thousand 
deaths related to the acquired immunodeficiency syndrome (AIDS) in the world, in 
20191. Despite the advances promoted by the antiretroviral therapy (ART), including 
substantial increase in life expectancy, turning HIV from a fatal disease to a chronic 
condition, the disease remains a public health challenge worldwide2.
Patients infected with HIV are at high risk for developing critical diseases due 
to their advanced immunosuppression, increased susceptibility to tuberculosis 
and bacterial sepsis and underlying comorbidities, which are associated with 
their more frequent admission to intensive care units (ICUs)3,4. Other leading 
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causes of hospitalization include drug toxicity, hepatitis 
B or C coinfection, cardiomyopathy, renal injury, chronic 
pulmonary disease and cirrhosis3.
Renal impairment, mainly represented by chronic 
kidney disease and end-stage renal disease, is a risk factor 
for death among patients with HIV/AIDS5,6. Survival rates 
in patients undergoing hemodialysis are smaller than the 
ones observed in the general population7.
Considering the reduced number of studies with 
critical HIV patients in Brazil and the high mortality 
among hospitalized individuals, the present study aimed to 
investigate risk factors for death in patients with HIV/AIDS 
undergoing hemodialysis in an intensive care setting4,8. 
MATHERIALS AND METHODS
This is a retrospective cross-sectional study performed 
through the analysis of medical records from patients 
diagnosed with HIV/AIDS, who were admitted to the 
Intensive Care Unit (ICU) of an infectious disease hospital 
in Fortaleza, Ceara State, Brazil. Medical records from all 
HIV/AIDS patients admitted to the ICU from January 2013 
to November 2017, aged 18 years or over, regardless of 
the hospitalization cause, with positive serological tests 
to HIV (ELISA and Western Blot), in accordance with 
the recommendation of the Brazilian Ministry of Health. 
Medical records from cases in which it was not possible to 
identify the clinical outcome were excluded. The sample 
consisted of 271 patients who were divided into two 
different groups: those who underwent dialysis (n = 33) 
and those who did not (n = 238). Each of these groups was 
stratified according to the evolution to death or not.
Data collection was carried out by a team composed 
of a researchers previously trained in filling out the 
research form designed to assess the following clinical 
and demographic parameters available in medical records: 
age, gender, main signs and symptoms at the time of 
hospital admission (fever, chills, cough, dyspnea, diarrhea, 
vomiting, weight loss, asthenia, myalgia, anorexia, oliguria, 
disorientation, seizures, headache, chest pain, abdominal 
pain and low back pain), aside from presence of renal injury, 
coinfection with HBV or HCV, opportunistic diseases, use 
of ART, habitsand length of hospitalization. There was 
also a data collection related to the following laboratory 
tests: CD4 count, viral load, hemoglobin, hematocrit, white 
blood cells (WBC) count, platelets count, serum urea, 
serum creatinine, plasma sodium, plasma potassium, lactic 
dehydrogenase (LDH), aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT). 
Statistical analysis was performed using the Statistical 
Package for Social Science (SPSS), version 20.0 for 
Windows (IBM Corp., Armonk, New York, USA). Death 
during treatment was defined as the study outcome. This 
variable was verified by the stratification of dialysis in 
order to identify the possible effect of dialysis on mortality. 
The predictive variables of the study were related to 
sociodemographic characteristics, comorbidities, previous 
and current ART and laboratory tests. All variables were 
collected through medical records.
For data analyses, the nominal variables were described 
using simple and relative frequencies, and, for numerical 
variables, the median and the interquartile range were 
presented. The predictor variables were compared based 
on the occurrence of death or not, using the chi-square 
test (for nominal variables) or the Wilcoxon test (for 
numerical variables). A P-value < 0.05 was considered 
statistically significant. This same process was performed 
for the stratification by dialysis. Crude and adjusted odds 
ratios (ORs) were calculated, as well as 95% confidence 
intervals (CIs).
For the regression analysis, the logistic model was used. 
Firstly, the variables with a p-value < 0.20 were used in 
the bivariate analysis and by a step-by-step model, and the 
exclusion of variables whose p-values were > 0.05. The 
final model was adjusted for the variables with a p-value < 
0.05. For the stratified analysis, the significant variables of 
the bivariate analysis were selected and the same previous 
method was adopted for the final adjustment. It should be 
noted that in all regression models the total CD4 count was 
not used as a variable because the models did not converge.
The research was submitted to and approved by 
the Medical Ethics Committee of Hospital Sao Jose of 
Infectious Diseases, under the process Nº 284.915.
RESULTS
The prevalence of death among all the patients was 
19.1% (95% CI: 14.8-24.3). Most of the patients were 
male (196 [71.3%]), and the median age was 47 years. 
Only 208 (76.7%) used ART, and lamivudine was the most 
commonly used drug (195 [80.9%]). The main cause of 
hospitalization was pulmonary tuberculosis (50 [16.9%]), 
followed by neurotoxoplasmosis (50 [14.9%]). The most 
frequent symptoms were fever (174 [63.7%]) and chills 
(234 [86.0%]). Diabetes mellitus was the most prevalent 
comorbidity (27 [10.0%]). In addition, 33 (18.2%) patients 
underwent hemodialysis. 
When stratified by the need for hemodialysis, there 
were differences between the two group. For patients 
who did not undergo hemodialysis, age, fever, dyspnea, 
oliguria, disorientation, kidney injury, use of lamivudine and 
efavirenz, length of hospitalization, CD4 count, WBC count, 
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platelet count, urea, sodium and LDH were the associated 
variables. For patients who underwent hemodialysis, the use 
of stavudine, abacavir and ritonavir, as well as the length 
of hospitalization were associated factors (Tables 1 and 2).
For patients who did not undergo dialysis, each 
increment of one year of age, increased the chances of death 
by 6% (95% CI: 1.03-1.10). Dyspnea was associated with 
a 3.9-fold risk of death (95% CI: 1.48-10.31). Concerning 
laboratory parameters, an increase in the WBC was 
associated with a slightly increased risk of death (p = 0.03), 
and an increase in the platelet count decreased the risk of 
death by 1% (95% CI: 0.998-0.999). Among patients who 
required hemodialysis, the logistic regression model did not 
reach convergence when the use of stavudine was present, 
Table 1 - Demographic characteristics and factors associated with death stratified by the need of undergoing dialysis.
Patients who needed hemodialysis 
N=33
Patients who did not need hemodialysis 
N=238
N(%) p OR IC N(%) p OR IC
Age (years) 61 (50-66) 0.983 1.05 1.02-1.08 61 (56-68) <0.001 1.00 0.94-1,06
Gender (male) 18 (72.0) 0.601 1.08 0.45-2.57 21 (12.4) 0.857 1.54 0.28-8.25
Fever 12 (63.2) 0.341 2.91 1.06-7.95 24 (15.6) 0.030 0.46 0.10-2.27
Dyspnea 12 (75.0) 0.520 3.81 1.67-8.71 18 (21.2) 0.001 1.63 0.36-7.38
Oliguria 6 (50.0) 0.063 8.24 1.57-43.01 3 (50.0) 0.003 0.23 0.04-1.13
Disorientation 8 (80.0) 0.396 3. 90 1. 72-8. 82 13 (26.5) 0.001 2.13 0.36-12.53
Alcoholism 8 (66.7) 0.775 0.78 0.32-1.88 8 (9.6) 0.584 0.8 0.17-3.68
Smoking 4 (66.7) 0.858 0.55 0.20-1.54 5 (7.5) 0.255 0.84 0.13-5.60
Renal failure 16 (64.0) 0.208 4.23 1.63-10.99 8 (32.0) 0.002 0.25 0.02-2.40
Opportunistic diseases 12 (70.6) 0.909 0.48 0.21-1.08 12 (8.8) 0.072 1.10 0.25-4.81
Table 2 - Antiretroviral therapy and laboratory tests associated with death, stratified by the need of undergoing dialysis.
N(%) p OR IC N(%) p OR IC
ARVT 13 (61.9) 0.198 0.27 0.12-0.62 16 (8.6) 0.001 0.33 0.06-1.87
ARVT time (days) 36 (1-158) 0.813 1.00 0.99-1.00 12 (0-73) 0.679 0.99 0.98-1.00
3TC 9 (50.0) 0.034 0.23 0.09-0.55 16 (9.1) <0.001 0.11 0.02-1.06
ABC 2 (28.6) 0.029 0.47 0.06-3.80 1 (7.7) 0.472 0.13 0.02-0.91
TDF 6 (54.5) 0.268  0.56 0.24-1.31 10 (9.9) 0.179 0.4 0.08-2.06
LPV 3 (100.0) 0.166 1.70 0.57-5.05 5 (20.8) 0.332 *** ***
RTV 2 (28.6) 0.017 1.26 0.39-4.02 4 (16.7) 0.702 0.11 0.01-0.77
EFZ 5 (55.6) 0.573 0.40 0.18-0.93 10 (8.8) 0.031 0.62 0.12-3.22
NVP 2 (100.0) 0.284 *** *** 0 (0.0) 0.203 *** ***
CD4 (absolute) 143 (51-478) 0.782 1,002 1,0003-1,004 363 (232-517) 0.018 0.99 0.99-1.00
VC (absolute) 364 (0-70,814) 0.664 0,99 0,99-1,00 305 (0-3.778) 0.284 0.99 0.99-1.00
Na+ (mEq/L) 137 (130-144) 0.817 1,08 1,01-1,16 139 (132-143) 0.022 1.00 0.93-1.10
K+ (mEq/L) 4.7 (3.9-5.7) 0.293 1,39 0,88-2,19 4.1 (3.5-4.55) 0.150 1.49 0.70-3.13
WBCs /mm3 6,780 (2,710-12,400) 0.556 1,00007 1,00001-1,001 7,590 (5,220-11,500) 0.0009 1.00 0.99-1.00
Lymphocytes /mm3 790 (290-1,310) 0.335 0,99 0,99-1,00 370 (11-804) 0.361 0.99 0.99-.00
Platelets /mm3 138 (79,000-199,000) 0.458 0,994 0,990-0,999 172,000 (70,500-218,000) 0,012 0.99 0.99-1.00
LDL (mg/dL) 1,151 (616-1,749) 0,.061 1,005 1,0002-1,001 610 (429-850) 0,040 1.00 0.99-1.00
Ureia (mg/dL) 104 (51-185) 0.936 1,02 1,01-1,04 54 (35-91) <0,001 1.00 0.99-1.00
Creatinine (mg/dL) 2.4 (2-6.8) 0.880 1,45 0,95-2,20 1.0 (0.7-1.7) 0.086 0.98 0.81-1.18
Length of Hospitalization (days) 7 (14-21) 0.028 0,95 0,91-0,99 11 (5-13) 0.035 0.95 0.91-0.99
ARVT = antiretroviral therapy; AZT = zidovudine; 3TC = lamivudine; d4T = stavudine; ABC = abacavir; TDF = tenofovir; LPV = lopinavir; ATV = atazanavir; 
IDV = indinavir; NFV = nelfinavir; RTV = ritonavir; EFZ = efavirenz; NVP = nevirapine; DM = diabetes mellitus; HCV = hepatitis C virus; HBV = hepatitis 
B virus; VC = viral charge; Hb = hemoglobin; HTC = hematocrit; WBC = white blood cells; LDL = low density lipoproteins; Ur = urea; Cr = creatinine; 
AST = aspartate aminotransferase; ALT = alanine aminotransferase.
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so it was removed. Considering the remaining variables, the 
length of the treatment was the only variable that remained 
associated. Thus, the increase of one day in the length of 
hospital stay reduced the chances of death by 5% (95% CI: 
0.90-0.99) (Table 3).
DISCUSSION
In patients who did not need hemodialysis, age, fever, 
dyspnea, oliguria, disorientation, kidney injury, use of 
lamivudine and efavirenz, length of hospitalization, 
WBC count, platelet count, urea, sodium and LDH were 
associated factors. For the ones who needed hemodialysis, 
the use of stavudine, abacavir and ritonavir, and the length 
of hospitalization were factors associated with death. 
The overall death rate in the present study was twice as 
high as that found in a previous cohort study conducted in 
the Southeast region of Brazil9, however it is lower than the 
general prevalence found in the Northeast region (22%)10. 
Despite the free access to ART nationwide, late diagnosis 
and difficulties in accessing the therapy are still frequent, 
which result in a greater risk for severe immunodepression 
and, consequently, increasing the chances of ICU 
hospitalization.. Therefore, there is a need to improve public 
policies aimed at the prompt diagnosis and initiation of ART 
in HIV/AIDS patients in the country’s Northeast region, 
as a way to guarantee the early identification of cases and 
thus preventing severe immunodepression, opportunistic 
infections, hospitalizations and death.
This study demonstrated a predominance of elderly 
patients in the ICU and association between the increasing 
of age and death. This confirms a trend of life expectancy 
increment among patients with HIV, which results in an 
increasing proportion of infected patients over the age of 
50 years, especially in low-income countries. It also stands 
out the greater chance of HIV infection in the elderly11.
This finding is an alert for health professionals to 
screen HIV among the elderly at the time of admission to 
the ICU, prior to hospitalization, thus enabling an early 
diagnosis and the beginning of treatment in a timely manner, 
mainly because the symptoms of AIDS may resemble 
manifestations that are common to aging, as well as other 
comorbidities and chronic conditions12.
In addition, some evidence points to a reduced survival 
of elderly people after the HIV diagnosis and an increased 
risk of disease progression among those with suboptimal 
adherence to treatment13. Therefore, it is necessary 
to reinforce the quality of interdisciplinary outpatient 
monitoring in this age group, so as to recognize factors 
associated with non-adherence to treatment and to provide 
an adequate management of associated comorbidities.
Pulmonary tuberculosis stood out as the main cause 
of admission to the ICU, in line with the literature14. 
Approximately 1 to 3% of HIV/tuberculosis coinfection 
cases need to be referred to the Intensive Care Unit, with 
death rates ranging from 2 to 67%15. Interventions are 
needed to prevent and control tuberculosis cases, such as 
early diagnosis, case control and effective treatment, with 
a focus on reducing the impact of this coinfection on the 
mortality of people with HIV16.
Concerning symptoms that were related to death among 
patients who did not need hemodialysis, fever, dyspnea, and 
disorientation are associated with opportunistic respiratory 
diseases, commonly found in patients who need medical 
assistance in intensive care settings14. Oliguria was also 
associated with death in this group, which may be related to 
the development of kidney injuries, a worsening prognosis 
factor in critically ill patients3. No other symptoms 
associated with greater chances of death were identified 
among patients who needed hemodialysis.
The occurrence of non-transmissible comorbidities, 
such as diabetes, among the investigated population also 
corresponds to the literature, being related to chronic 
inflammation in patients with HIV due to chronic immune 
activation, treatment failure, as well as socioeconomic 
and behavioral factors in this population17-19. It is worth 
mentioning that preexisting chronic conditions can make 
HIV patients who are critically ill, more susceptible to 
kidney disease during their ICU stay20.
Given the risk posed by the variety of chronic non-
infectious diseases to which patients with HIV are exposed, 
additional care is needed, focusing on improving the 
lifestyle of this population, providing a better control of 
sociodemographic and behavioral factors, in addition to other 
chronic comorbidities, with integration between specialized 
HIV care services and primary health care ones21.
Table 3 - Logistic regression analysis on the chances of death 
for the studied sample according to the need of dialysis.
Patients who did not undergo dialysis
OR CI 95% P-value
Age 1.06 1.03-1.10 < 0.001
Dyspnea 3.90 1.48-10.31 0.01
WBCs count 1.00001 1.000005-1.0001 0.03
Platelets count 0.99 0.998-0.999 0.01
Patients who underwent dialysis
OR CI 95% P-value
ABC 0.22 0.02-2.62 0.23
RTV 0.12 0.01-1.24 0.08
Length of hospitalization 0.95 0.90-0.99 0.04
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CD4 count was associated with death among patients 
who did not need hemodialysis, in agreement with previous 
studies carried out in critically ill HIV patients22-24. This 
association was already expected, since decreasing levels of 
CD4 cells reflect a weaker immune status, being associated 
with an increased risk of opportunistic infections with great 
clinical severity. However, this factor was not associated 
with death among HIV patients on hemodialysis, diverging 
from a previous retrospective cohort study carried out 
in an outpatient service in Cameroon in which severe 
immunodepression was associated with a decrease in the 
survival rate among those patients6. This difference may be 
related to the fact that, in the present study, hemodialysis 
has probably started during the ICU stay.
The length of hospitalization was a contributing factor 
to death in both strata, with a median of 7 days for patients 
who needed hemodialysis and died, and 11 days for 
patients who did not need hemodialysis, similar to results 
found in other studies25,26. This is an important indicator 
for assessing the quality of care provided to ICU patients, 
therefore, future research should assess HIV patients’ care 
in this scenario.
In view of this finding, it is necessary to reflect on the 
difficulties of access of HIV-positive patients to ICUs within 
the scope of the Unified Health System (SUS), which can 
prolong the length of stay and the severity of the clinical 
condition, increasing the risk of unfavorable outcomes.
The use of antiretroviral therapy improved survival 
among patients who did not undergo dialysis. However, it 
did not follow the same trend among patients who required 
it. This finding may be related to the fact that the beneficial 
effects of ART are attenuated by a greater severity of critical 
illnesses27. On the other hand, the potentially toxic effect 
of ART stands out, which can trigger the inflammatory 
syndrome of immune reconstitution, leading to death28. 
These results highlight the challenges of using 
antiretrovirals in critically ill patients, such as dose control, 
absorption problems, recognition of drug interactions, 
identification of toxic effects and suspension of antiretroviral 
treatment29. Therefore, specialists need to balance the risks 
and benefits of continuous use of antiretrovirals among 
critically ill patients.
In the present study, the use of lamivudine and efavirenz, 
which are drugs with low renal toxicity, was related 
to death among patients that did not undergo dialysis. 
The literature points out that these drugs have adverse 
effects (dermatological, gastrointestinal symptoms and 
neuropsychiatric disorders) that may lead the patient to 
discontinue the treatment30. Consequently, these patients are 
more susceptible to opportunistic infections, hospitalization 
and death.
Among those who underwent dialysis, the use of 
stavudine, abacavir and ritonavir was significantly 
associated with a higher risk of death. In the literature, 
these antiretroviral drugs are identified among those that 
can cause kidney injuries31. The use of these drugs may 
justify the need for hemodialysis, which in turn is a factor 
that has been shown to reduce the survival rate of critically 
ill patients7.
The limitations of this study include its retrospective 
design, missing data in several medical records and its 
local character, which limits the generalization of results.
AUTHORS’ CONTRIBUTIONS
MGC, EDF, GBSJ e RJPN participated in the conception, 
design and writing of the article. MSRP, PEACG, GCM 
participated in the collection and interpretation of the data. 
All authors participated in the critical review and approval 
of the version to be published.
REFERENCES
 1. Joint United Nations Programme on HIV/AIDS. Global AIDS 
update: 2020. Geneva: UNAIDS; 2020. [cited 2021 Mar 19]. 
Available from: https://www.unaids.org/sites/default/files/
media_asset/2020_global-aids-report_en.pdf
 2. Silva Junior GB, Parente Filho SL, Soares DS, Alencar RN, 
Peixoto TT, Nogueira IS, et al. Acute kidney injury and other 
factors associated with mortality in HIV-infected patients. Rev 
Assoc Med Bras. 2018;64:509-17.
 3. Barbier F, Mer M, Szychowiak P, Miller RF, Mariotte E, Galicier 
L, et al. Management of HIV-infected patients in the intensive 
care unit. Intensive Care Med. 2020;46:329-42.
 4. Luna LD, Soares DS, Silva Junior GB, Cavalcante MG, Malveira 
LR, Meneses GC, et al. Clinical characteristics, outcomes and 
risk factors for death among critically ill patients with HIV-
related acute kidney injury. Rev Inst Med Trop Sao Paulo. 
2016;58:52.
 5. Jotwani V, Li Y, Grunfeld C, Choi AI, Shlipak MG. Risk factors 
for ESRD in HIV-infected individuals: traditional and HIV-
related factors. Am J Kidney Dis. 2012;59:628-35.
 6. Halle MP, Edjomo AM, Fouda H, Djantio H, Essomba N, 
Ashuntantang GE. Survival of HIV infected patients on 
maintenance hemodialysis in Cameroon: a comparative study. 
BMC Nephrol. 2018;19:166.
 7. Wyatt CM. Kidney Disease and HIV infection. Top Antivir Med. 
2017;25:13-6.
 8. Azoulay E, Castro N, Barbier F. Critically ill patients with HIV: 
40 years later. Chest. 2019;157:293-309.
 9. Coelho LE, Ribeiro SR, Veloso VG, Grinsztejn B, Luz PM. 
Hospitalization rates, length of stay and in-hospital mortality in 
Cavalcante et al.
Rev Inst Med Trop São Paulo. 2021;63:e33Page 6 of 6
a cohort of HIV infected patients from Rio de Janeiro, Brazil. 
Braz J Infect Dis. 2017;21:190-5.
 10. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
HIV/Aids: 2019. Bol Epidemiol. 2019;N. Esp:1-70. [cited 
2021 Mar 19]. Available from: http://www.aids.gov.br/pt-br/
pub/2019/boletim-epidemiologico-de-hivaids-2019
 11. Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys 
P. Global and regional trends of people living with HIV aged 
50 and over: estimates and projections for 2000-2020. PLoS 
One. 2018;13:e0207005.
 12. Alencar RA, Ciosak IS. O diagnóstico tardio e as vulnerabilidades 
dos idosos vivendo com HIV/AIDS. Rev Esc Enferm USP. 
2014;49:229-35.
 13. Ghidei L, Simone MJ, Salow MJ, Zimmerman KM, Paquin AM, 
Skarf LM, et al. Aging, antiretrovirals, and adherence: a meta 
analysis of adherence among older HIV-infected individuals. 
Drugs Aging. 2013;30:809-19.
 14. Souza PN, Miranda EJ, Cruz R, Forte DN. Cuidados paliativos 
no paciente com HIV/AIDS internado na unidade de terapia 
intensiva. Rev Bras Ter Intensiva. 2016;28:301-9.
 15. Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Dalcin PT. 
Mortality among patients with tuberculosis requiring intensive 
care: a retrospective cohort study. BMC Infect Dis. 2010;10:54.
 16. Ferreira MD, Neves CP, Souza AB, Beraldi-Magalhães F, Migliori 
GB, Kritski AL, et al. Predictors of mortality among intensive 
care unit patients coinfected with tuberculosis and HIV. J Bras 
Pneumol. 2018;44:118-24.
 17. Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Van 
Sighem A, et al. Future challenges for clinical care of an ageing 
population infected with HIV: a modelling study. Lancet Infect 
Dis. 2015;15:810-8.
 18. Shivakoti R, Gupte N, Tripathy S, Poongulali S, Kanyama C, 
Berendes S, et al. Inflammation and micronutrient biomarkers 
predict clinical HIV treatment failure and incident active 
TB in HIV-infected adults: a case-control study. BMC Med. 
2018;16:161.
 19. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks 
JT, et al. Cigarette smoking prevalence among adults with 
HIV compared with the general adult population in the United 
States: cross-sectional surveys. Ann Intern Med. 2015;162:335-
44.
 20. Lopes JA, Melo MJ, Raimundo M, Fragoso A, Antunes F. Long-
term risk of mortality for acute kidney injury in HIV-infected 
patients: a cohort analysis. BMC Nephrol. 2013;14:32.
 21. Yang HY, Beymer MR, Suen SC. Chronic disease onset among 
people living with HIV and AIDS in a large private insurance 
claims dataset. Sci Rep. 2019;9:18514.
 22. Vincent B, Timsit JF, Auburtin M, Schortgen F, Bouadma L, 
Wolff M, et al. Characteristics and outcomes of HIV-infected 
patients in the ICU: impact of the highly active antiretroviral 
treatment era. Intensive Care Med. 2004;30:859-66.
 23. Croda J, Croda MG, Neves A, Santos SS. Benefit of antiretroviral 
therapy on survival of human immunodeficiency virusinfected 
patients admitted to an intensive care unit. Crit Care Med. 
2009;37:1605-11.
 24. Chiang HH, Hung CC, Lee CM, Chen HY, Chen MY, Sheng WH, 
et al. Admissions to intensive care unit of HIV-infected patients 
in the era of highly active antiretroviral therapy: etiology and 
prognostic factors. Crit Care. 2011;15:R202.
 25. Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons 
for hospitalization in a multisite United States cohort of persons 
living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 
2012;59:368-75.
 26. Long LC, Fox MP, Sauls C, Evans D, Sanne I, Rosen SB. The 
high cost of HIV-positive inpatient care at an urban hospital 
in Johannesburg, South Africa. Plos One. 2016;11:e0148546.
 27. Dickson SJ, Batson S, Copas AJ, Edwards SG, Singer M, Miller 
RF. Survival of HIV-infected patients in the intensive care 
unit in the era of highly active antiretroviral therapy. Thorax. 
2007;62:964-8.
 28. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of patients 
with HIV infection. N Engl J Med. 2006;355:173-81.
 29. Andrade HB, Shinotsuka CR, Silva IR, Donini CS, Li HY, 
Carvalho FB, et al. Highly active antiretroviral therapy for 
critically ill HIV patients: a systematic review and meta-
analysis. PLoS One. 2017;12:e0186968.
 30. Azevedo LN, Ximenes RA, Monteiro P, Montarroyos UR, 
Miranda-Filho DB. Factors associated to modification of 
first-line antiretroviral therapy due to adverse events in people 
living with HIV/AIDS. Braz J Infect Dis. 2020;24:65-72.
 31. McLaughlin MM, Guerrero AJ, Merker A. Renal effects of non-
tenofovir antiretroviral therapy in patients living with HIV. 
Drugs Context. 2018;7:212519.
